NEX Health Intelligence Lands €1M to Map Hospital Superbug Spread

Healthcare-associated infections hit roughly 4.3 million European patients a year, contribute to more than 90,000 deaths, and account for around 71% of antibiotic-resistant infections recorded across the continent. NEX Health Intelligence, a four-year-old Imperial College London spinout building an AI platform that maps how those infections move through hospital wards, has just closed a €1 million pre-seed.

The check, led by Brighteye Ventures, a London-based fund best known for European edtech bets, is modest by clinical-software standards. The deployment list is not. NEX says its platform has already supported infection safety across more than 40,000 patient admissions, spanning UK National Health Service (NHS) trusts, a military hospital in Southeast Asia, and an expanding set of Malaysian sites.

The €1M Round in Context

The pre-seed values cash plus mission. Brighteye led; the syndicate ran wide. Adeline Arts & Science, AFI Ventures, Momentous Ventures, the Conception X Angel Syndicate and an unnamed group of industry operator angels filled out the remainder.

Imperial College London’s enterprise team confirmed the round on 19 May, alongside disclosure that the company has now raised €1.4 million in total since being incorporated in 2022 by founder Dr Ashleigh Myall.

For a regulated software company that has to ship into clinical environments under formal compliance and clinical safety governance, €1 million is roughly 18 months of runway in the UK at a tight burn. NEX says the proceeds will fund regulatory approval work, evidence generation from live deployments, and continued sales motion into NHS trusts and overseas hospitals.

Europe’s HAI Burden Is Rising Faster Than Surveillance

The market case for infection AI sits in the latest ECDC point-prevalence survey, which estimates that 4.3 million patients acquire at least one healthcare-associated infection (HAI, an infection picked up during clinical care) per year across 28 EU/EEA countries and three western Balkan states. The European Centre for Disease Prevention and Control puts the annual death toll above 90,000 and the associated burden at roughly 2.5 million disability-adjusted life years.

The mix matters. Respiratory tract infections account for 29.3% of cases, urinary tract infections for 19.2%, surgical-site infections for 16.1%, and bloodstream infections for 11.9%.

Around 32% of the microorganisms detected in those infections are resistant to antimicrobials, and HAIs make up roughly 71% of all infections caused by antibiotic-resistant bacteria across the bloc. That share is the antimicrobial-resistance pipeline running through European hospital systems, and it has been climbing in successive ECDC surveys.

What is stretching the gap is the cost-and-staffing squeeze inside infection prevention and control teams.

• 4.3 million European hospital patients acquire a HAI each year, per ECDC.
• 90,000+ deaths annually are linked to those infections.
• 50% of HAIs are estimated to be preventable with stronger surveillance.
• 71% of EU/EEA antibiotic-resistant infections occur inside healthcare facilities.

That preventable share is the hook every infection-AI startup pitches into. Manual ward-by-ward surveillance, the system most European hospitals still run, scales linearly with patient throughput and badly with staff turnover. The clinical-decision-support layer NEX is building is what trust managers describe, off the record, as the most realistic route to cutting the manual workload without cutting the underlying programme.

How NEX’s Platform Reads the Hospital Network

The technical idea comes out of Dr Myall’s PhD at Imperial, supervised by mathematics professor Mauricio Barahona and the Fleming Initiative’s Professor Alison Holmes. The method builds contact networks from routinely collected hospital bed records, identifying which wards, shifts and patient pathways are statistically likely to seed the next outbreak before swabs come back from the lab. The shipping product splits that core capability into three named modules:

• Risk Intelligence: patient-level scoring that flags individuals at elevated risk of acquiring or carrying a resistant pathogen, drawn from bed history, contact graphs and clinical metadata.
• Outbreak Intelligence: cluster detection and investigation tools that map likely transmission routes once an index case is identified, surfacing the wards and contacts that need immediate screening.
• Surveillance Intelligence: automation of the routine reporting infection-control teams currently produce by hand, including standardised metrics for trusts and ministries of health.

NEX claims the platform has cut active surveillance testing requirements by up to 68%, increased screening compliance by 44%, and reduced the time clinicians spend on case review by 87% inside its existing deployments. Those figures come from the company’s own customer reporting and have not yet appeared in peer-reviewed form, a gap the pre-seed proceeds are now meant to close.

The compliance scaffolding is more developed. The product is approved under the NHS Digital Technology Assessment Criteria (DTAC, the standard NHS clinical-software intake check), compliant with the Data Security and Protection Toolkit (DSPT, the NHS data-handling baseline), Cyber Essentials Plus certified, and carries DCB0129 clinical safety certification, the minimum stack any clinical-decision-support vendor needs to procure into a UK trust.

Brighteye’s Crossover Bet From Edtech to Infection AI

Brighteye Ventures has built its reputation as the most active European education-technology fund, with roughly €150 million across two vehicles and portfolio names that read as edtech: Hack The Box, Ornikar, Ironhack, Sdui. The fund’s investment mandate has always covered healthcare and software, but the public deal-flow has skewed heavily toward learning platforms.

The NEX cheque is the kind of conviction call that signals a thesis tilt. Founding partner Ben Wirz and principal Isabella Vahdati framed the bet around AI’s potential in high-stakes clinical environments.

AI has the potential to enable intelligent decision support in high-stakes environments.

That is the public line. The private reading is that European pre-seed cheques into AI-native clinical-decision-support are landing well below US comparables, while UK regulatory machinery has produced exactly the compliance stack NEX has cleared. Other European healthtech rounds this year have flagged the same gap, with Pontiro’s £357k healthcare-AI raise landing in a similar bracket earlier in 2026.

The upside read is straightforward: if NEX clears the evidence bar over the next 18 months, the platform becomes infrastructure for every NHS trust running its own surveillance team, with an obvious international export ramp from the existing Asia footprint.

From Two London Trusts to a Malaysian Military Hospital

The deployment list is unusual for a pre-seed clinical-AI vendor, in that it crosses two continents and includes both civilian NHS and overseas military settings. The 40,000-admission figure NEX cites is the cumulative result of that spread, not any single site.

UK NHS Footprint

NEX is running active evaluation projects across two London NHS Trusts and a new deployment in the North West of England. The trust names are not public, a normal restriction during evaluation phases when procurement governance prefers anonymity until clinical outcomes data is published.

The pattern matters more than the names. Each NHS evaluation feeds into the evidence dossier the company needs for wider procurement, and the regional split between London and the North West gives NEX cluster data from two operationally distinct patient populations and trust IT estates. Other UK healthcare-AI companies have followed a similar template, building from London teaching hospitals outward into regional acute trusts.

Southeast Asia and the Malaysia Pipeline

The international footprint anchors on Phramongkutklao Hospital, a Thai military facility where Dr Vasin Vasikasin, an assistant professor and infectious diseases physician, leads infection prevention and control. NEX has used that site as a public case study, the only named hospital partner on its website.

Malaysia is the active expansion lane. Public reporting from the company refers to projects across multiple Malaysian hospital sites without naming the trusts, mirroring the UK approach. European AI healthcare vendors targeting Asian rollouts have generally found procurement cycles shorter than UK ones once a flagship deployment exists, in part because hospital IT estates abroad tend to be greenfield rather than retrofitted.

The asymmetry is worth flagging: the Asia deployments are operationally further along than the UK ones, but the evidence dossier the regulatory work is meant to produce will be UK-led, because that is where the published trust evaluations sit.

What Could Stall the Rollout

The case for AI-native infection control is unusually well-documented on the demand side. The case for any single vendor capturing it is not. Three pressure points sit between this pre-seed and the next round.

• Peer-reviewed evidence gap. The 68%, 44% and 87% headline figures are vendor-reported. Until they appear in a peer-reviewed clinical journal with NHS data behind them, larger trusts and continental procurement teams will discount them.
• UKCA and MHRA regulatory clock. Clinical-decision-support tools sit awkwardly across the Medicines and Healthcare products Regulatory Agency (MHRA) software classification and the post-Brexit UK Conformity Assessed (UKCA) marking regime. The proceeds are meant to fund that work; it is not yet finished.
• Antimicrobial stewardship budget. Infection prevention and control budgets across the NHS were squeezed through the post-pandemic spending review, and the share of trust IT spend allocated to AI-native clinical software remains small. NEX needs that line item to grow.

The competitive set is also thickening. Other European AI surveillance vendors are circling the same trusts, and US incumbents in hospital epidemiology software have started shipping AI features inside their existing contracts. None of them have NEX’s contact-network mathematics, but several have salesforce coverage a pre-seed company does not.

For now, the gating question is the published evidence base. The 40,000 admissions already in the system are the dataset; the next 12 months are when they have to translate into peer-reviewed numbers.

If that evidence arrives ahead of the seed round, NEX’s next cheque gets priced off a different curve. If it slips, the £900,000 the company has just collected has to stretch through a longer regulatory winter than the burden math suggests it should need to.